Abstract 3726: Design of personalised polymer based combination therapeutics for advanced stage breast cancer patients

2018 ◽  
Author(s):  
Ana Armiñán ◽  
Zoraida Andreu ◽  
Juan J Arroyo-Crespo ◽  
David Charbonnier ◽  
Esther Masiá ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Advanced Stage ◽  
Breast Cancer Patients

scholarly journals Pengkajian dan Symptom Mangement Pada Pasien Dengan Fungating Breast Cancer di Pelayanan Perawatan Paliatif: Literature Review

2021 ◽  
Vol 8 (1) ◽  
pp. 61-74
Author(s):  
Yodang Yodang ◽  
Nuridah Nuridah
Keyword(s):  
Breast Cancer ◽  
Palliative Care ◽  
Literature Review ◽  
Cancer Patients ◽  
Breast Cancer Incidence ◽  
Assessment Tools ◽  
Advanced Stage ◽  
Breast Cancer Patients ◽  
Palliative Care Setting ◽  
Palliative Care Services

Currently, cancer includes breast cancer is a predominant disease treated in palliative care services. Breast cancer incidence increased significantly during the last decade and can progress to a late or advanced stage. At this advanced stage, the incidence of the fungating wound occurs in 5-10% of breast cancer patients. The study aims to identify assessment and symptoms management of fungating breast cancer in the palliative care setting. This study applied a literature review method. Searching for articles using 4 journal databases including DOAJ, Google Scholar, Proquest, and Science Direct. 17 articles that met the inclusion criteria of the study. The literature review identifies that the assessment tools are holistic assessment methods, wound assessment charts, and time framework assessments. The major symptoms are mal-odor, pain, exudation, peri-wound maceration and bleeding, psychological and spiritual issues. The studies, which focus on assessment and symptoms management of fungating breast cancer was limited. This affects the comprehensiveness of the review study. Investigation on quality of life among fungating breast cancer patients shortly is needed.   

scholarly journals Prevalence and Predictors of Complementary Therapy Use in Advanced-Stage Breast Cancer Patients

2007 ◽  
Vol 3 (6) ◽  
pp. 292-295 ◽  
Author(s):  
Abigail M. Gross ◽  
Qin Liu ◽  
Susan Bauer-Wu
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Physical Exercise ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Complementary Therapy ◽  
Spiritual Practices ◽  
Advanced Stage ◽  
Breast Cancer Patients ◽  
Stage Iv Breast Cancer

Purpose Information on the use of complementary therapies in patients with advanced-stage cancer is limited. Given the disease and treatment complexities associated with the care of patients with metastatic cancer, oncology clinicians would benefit from having an appreciation of the extent of usage of unconventional, adjunctive therapies among these patients. This study evaluated the prevalence and demographic predictors of complementary therapy use in a sample of women with metastatic breast cancer. Methods Subjects with stage IV breast cancer were recruited from six treatment facilities in New England. A written, mailed survey assessing complementary therapy use and sociodemographic information was completed by each subject, while disease and treatment information was obtained from medical records. Descriptive statistics and multivariate logistic regression analyses were conducted. Results Of the 173 participants, 78% used at least one type of complementary therapy, 43% used two or more types, and 23% used three or more types, excluding spiritual practices and physical exercise. When including spiritual practices and physical exercise, 90% used at least one complementary therapy, 70% used two or more types, and 45% used three or more types. Visits to alternative health practitioners were predicted by younger age (P = .009) and higher education level (P = .002). Younger participants (P = .045) were more likely to use and spend more money on vitamins and herbal products (P = .02). Conclusions Use of unconventional therapies is pervasive among metastatic breast cancer patients, particularly among those who are younger and highly educated. Oncology providers need to assess patients' complementary therapy use and consider potential interactions with prescribed treatment protocols.

CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients

2007 ◽  
Vol 13 (9) ◽  
pp. 2714-2721 ◽  
Author(s):  
Sonia A. Perez ◽  
Michael V. Karamouzis ◽  
Dimosthenes V. Skarlos ◽  
Alexandros Ardavanis ◽  
Nectaria N. Sotiriadou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
Regulatory T Cell ◽  
Advanced Stage ◽  
Breast Cancer Patients ◽  
Cell Frequency ◽  
Her 2

scholarly journals Effect of chemotherapy on serum nitric oxide levels in advanced stage breast cancer patients

2019 ◽  
Vol 8 (1) ◽  
pp. 189
Author(s):  
Charushila Y. Kadam ◽  
Subodhini A. Abhang
Keyword(s):  
Breast Cancer ◽  
Nitric Oxide ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Stage Iv ◽  
Chemotherapy Cycle ◽  
Stage Iii ◽  
Healthy Controls ◽  
Advanced Stage ◽  
Breast Cancer Patients

Background: The role of nitric oxide is still unclear in advanced breast cancer patients undergoing adjuvant chemotherapy. This study was undertaken to investigate the effect of chemotherapy on serum nitric oxide levels in advanced stage breast cancer patients.Methods: In this observational study, clinically and histopathologically proven sixty female patients with advanced stage breast cancer were included. According to Tumor-Node-Metastasis (TNM) classification, patients were further grouped as stage III and stage IV. Thirty healthy and age-matched female controls were selected for comparison. Blood was collected from healthy controls and from breast cancer patients after surgery prior to chemotherapy and after three weeks of administration of first adjuvant chemotherapy cycle. Serum nitric oxide levels were measured by spectrophotometric method.Results: Significantly higher concentrations of serum nitric oxide were observed in breast cancer patients before chemotherapy in stage III (p<0.0001) and stage IV (p<0.0001) of the disease as compare to concentrations in healthy controls. The serum levels of nitric oxide were significantly decreased in stage III as well as stage IV of breast cancer patients after three weeks of receiving first adjuvant chemotherapy cycle as compare to levels before chemotherapy (p<0.0001), however serum nitric oxide levels were higher in stage III (p=0.0036) and stage IV (p<0.0001) of the disease as compare to healthy controls.Conclusions: Chemotherapy drug administration causes decrease in serum nitric oxide levels in advanced stages of breast cancer patients. Monitoring serum nitric oxide levels could be used to predict patients’ response to chemotherapy treatment in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document